AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 276: R1661-R1667, 1999;
0363-6119/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kiss, B.
Right arrow Articles by Schmetterer, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiss, B.
Right arrow Articles by Schmetterer, L.
Vol. 276, Issue 6, R1661-R1667, June 1999

Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide

Barbara Kiss1, Susanne Dallinger1, Oliver Findl2, Georg Rainer2, Hans-Georg Eichler1, and Leopold Schmetterer1,3

1 Departments of Clinical Pharmacology and 2 Ophthalmology and 3 Institute of Medical Physics, University of Vienna, A-1090 Vienna, Austria

Acetazolamide, a carbonic anhydrase inhibitor, is used orally in the treatment of primary and secondary open-angle glaucoma and induces ocular and cerebral vasodilation. Several in vitro studies have shown that carbonic anhydrase pharmacology and the L-arginine-nitric oxide (NO) pathway are closely related. We investigated the role of NO in acetazolamide-induced vasodilation on cerebral and ocular vessels in 12 healthy subjects in the presence or absence of NG-monomethyl-L-arginine (L-NMMA), a NO synthase inhibitor, and in the presence or absence of L-arginine, the precursor of NO. Acetazolamide was administered after pretreatment with either L-NMMA or placebo and either L-arginine or placebo. Pulsatile choroidal blood flow was assessed with laser interferometric measurement of fundus pulsation. In addition, mean blood flow velocity (MFV) in the middle cerebral artery (MCA) and ophthalmic artery (OA) was measured with Doppler sonography. Acetazolamide increased ocular fundus pulsation amplitude (FPA; +27%, P < 0.001) and MFV in the MCA (+38%, P < 0.001) and in the OA (+19%, P = 0.003). Administration of L-NMMA alone reduced FPA (-21%, P < 0.001) and MFV in the MCA (-11%, P = 0.030) but did not change MFV in the OA. All hemodynamic effects of L-NMMA were reversed by L-arginine. However, neither L-NMMA nor L-arginine altered acetazolamide-induced changes in cerebral or ocular hemodynamic parameters. The present data indicate that acetazolamide-induced hemodynamic changes are not mediated by NO. Which mediators other than NO are involved in the hemodynamic effects as induced by carbonic anhydrase inhibitors remains to be elucidated.

acetazolamide; cerebral blood flow; ocular blood flow; acidosis


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. T. Dorner, G. Garhofer, B. Kiss, E. Polska, K. Polak, C. E. Riva, and L. Schmetterer
Nitric oxide regulates retinal vascular tone in humans
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H631 - H636.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
A. H. M. Van Mil, A. Spilt, M. A. Van Buchem, E. L. E. M. Bollen, L. Teppema, R. G. J. Westendorp, and G. J. Blauw
Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans
J Appl Physiol, March 1, 2002; 92(3): 962 - 966.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online